文献速递胸部肿瘤

基于血液的生物标志物组合用于个体化肺癌风险评估

Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
PubMed 文献 · J Clin Oncol · 2022-01-07

本研究利用前列腺、肺、结直肠和卵巢(PLCO)癌症筛查试验的数据和生物标本进行盲法验证,评估由表面活性蛋白B前体、癌抗原125、癌胚抗原和细胞角蛋白19片段组成的四标志物蛋白组合(4MP)联合肺癌风险预测模型(PLCOm2012)与现行USPSTF筛查标准相比的性能。结果显示,4MP联合PLCOm2012模型在诊断前1年内的病例血清中AUC为0.85,相比USPSTF2021标准在敏感性和特异性上均有统计学显著改善,在吸烟包年≥10的PLCO参与者中可多识别9.2%的肺癌病例并减少13.7%的非病例转诊。

要点

  • 4MP联合PLCOm2012模型在诊断前1年内的病例血清中AUC为0.85(95%CI 0.82-0.88)。
  • 相比USPSTF2021标准,联合模型在敏感性和特异性上均有统计学显著改善。
  • 在吸烟包年≥10的PLCO参与者中,联合模型可多识别9.2%的肺癌病例并减少13.7%的非病例转诊。

核心结论

  • 基于血液的生物标志物组合联合PLCOm2012模型显著改善了肺癌筛查的风险评估。

研究设计与样本

  • 利用PLCO癌症筛查试验数据和生物标本进行的盲法验证研究。
  • 评估四标志物蛋白组合(4MP)联合PLCOm2012模型与USPSTF筛查标准相比的性能。
  • 在1299份肺癌诊断前采集的血清和8709份非病例血清中检测4MP。

主要发现

  • 4MP单独在诊断前1年内病例血清中的AUC为0.79(95%CI 0.77-0.82),在整个标本集中为0.74(95%CI 0.72-0.76)。
  • 4MP联合PLCOm2012模型在诊断前1年内病例血清中的AUC为0.85(95%CI 0.82-0.88)。
  • 联合模型中4MP的获益源于高特异性下敏感性的改善。
  • 相比USPSTF2021标准,联合模型在敏感性和特异性上均有统计学显著改善。
  • 在吸烟包年≥10的PLCO参与者中,联合模型相比USPSTF2021标准可多识别9.2%的肺癌病例(需年度筛查),并减少13.7%的非病例转诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether a panel of circulating protein biomarkers would improve risk assessment for lung cancer screening in combination with a risk model on the basis of participant characteristics. METHODS: A blinded validation study was performed using prostate lung colorectal ovarian (PLCO) Cancer Screening Trial data and biospecimens to evaluate the performance of a four-marker protein panel (4MP) consisting of the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment in combination with a lung cancer risk prediction model (PLCOm2012) compared with current US Preventive Services Task Force (USPSTF) screening criteria. The 4MP was assayed in 1,299 sera collected preceding lung cancer diagnosis and 8,709 noncase sera. RESULTS: The 4MP alone yielded an area under the receiver operating characteristic curve of 0.79 (95% CI, 0.77 to 0.82) for case sera collected within 1-year preceding diagnosis and 0.74 (95% CI, 0.72 to 0.76) among the entire specimen set. The combined 4MP + PLCOm2012 model yielded an area under the receiver operating characteristic curve of 0.85 (95% CI, 0.82 to 0.88) for case sera collected within 1 year preceding diagnosis. The benefit of the 4MP in the combined model resulted from improvement in sensitivity at high specificity. Compared with the USPSTF2021 criteria, the combined 4MP + PLCOm2012 model exhibited statistically significant improvements in sensitivity and specificity. Among PLCO participants with ≥ 10 smoking pack-years, the 4MP + PLCOm2012 model would have identified for annual screening 9.2% more lung cancer cases and would have reduced referral by 13.7% among noncases compared with USPSTF2021 criteria. CONCLUSION: A blood-based biomarker panel in combination with PLCOm2012 significantly improves lung cancer risk assessment for lung cancer screening.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fahrmann JF, Marsh T, Irajizad E, et al. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. J Clin Oncol. 2022. PMID: 34995129. doi:10.1200/JCO.21.01460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。